Adverum Biotechnologies - Company & Market Research Reports

Adverum is a gene therapy company that innovate and produce medicines for rare and eye diseases that do not have many existing treatments. Adverum focuses on 7 key areas such as: wAMD, A1T Deficiency, HAE, FA, Severe allergy, Color vision deficiency, and XLRS. Adverum biotechnologies was founded in 2006, and it is headquartered in Menlo park, California. The company was previously known as Avalanche Technologies but changed its name to Adverum Biotechnologies in May 2016. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.

Ophthalmology Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Ophthalmology Drug Development Pipeline Review, 2016

  • Report
  • 633 Pages
From
Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Gene Therapy for Age-related Macular Degeneration - A Pipeline Analysis Report - Product Thumbnail Image

Gene Therapy for Age-related Macular Degeneration - A Pipeline Analysis Report

  • Report
  • 71 Pages
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
Wet Age-related Macular Degeneration - Pipeline Insights, 2017 - Product Thumbnail Image

Wet Age-related Macular Degeneration - Pipeline Insights, 2017

  • Drug Pipelines
  • 106 Pages
From
Age Related Macular Degeneration - Pipeline Review, H2 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H2 2017

  • Drug Pipelines
  • 537 Pages
From
Age Related Macular Degeneration - Pipeline Review, H1 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H1 2017

  • Drug Pipelines
  • 527 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

  • Drug Pipelines
  • 267 Pages
From
T-Cell Immunotherapy Market (2nd Edition), 2017-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

  • Report
  • 654 Pages
From
T-Cell Immunotherapy Market (3rd Edition), 2018-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • Report
  • 850 Pages
From
Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026 - Product Thumbnail Image

Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026

  • Report
  • 240 Pages
From
CAR-T Therapies Market, 2018-2030 - Product Thumbnail Image

CAR-T Therapies Market, 2018-2030

  • Report
  • 548 Pages
From
Peanut Allergy - Pipeline Review, H1 2018 - Product Thumbnail Image

Peanut Allergy - Pipeline Review, H1 2018

  • Drug Pipelines
  • 107 Pages
From
Peanut Allergy - Pipeline Review, H2 2017 - Product Thumbnail Image

Peanut Allergy - Pipeline Review, H2 2017

  • Drug Pipelines
  • 86 Pages
From
Peanut Allergy - Pipeline Insight, 2018 - Product Thumbnail Image

Peanut Allergy - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Hypersensitivity - Pipeline Review, H2 2016 - Product Thumbnail Image

Hypersensitivity - Pipeline Review, H2 2016

  • Drug Pipelines
  • 313 Pages
From
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2018 - Product Thumbnail Image

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2018

  • Drug Pipelines
  • 83 Pages
From
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2018 - Product Thumbnail Image

Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2018

  • Drug Pipelines
  • 84 Pages
From
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018 - Product Thumbnail Image

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 91 Pages
From
Loading Indicator
adroll